Clinical Trials
Enrolling Trials
31-40 of 175
Advarra-ICH, A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine in Healthy Participants ≥5 Years of Age
Infectious Disease
Infectious Disease
Adult, Child
The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 18,000 healthy participants 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
WCG, ICH - DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
Melanoma
Adult
test ctms only PI update
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
ICH, CIRB, Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Breast
Adult
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB-A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer
Gastro-Intestinal (GI)
Adult
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - Rice Lake
2501 Main
Stevens Point, WI 54481
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
SIRB, A Window to Future Outcomes of Antihypertensive Therapy and Superimposed Preeclampsia for Mothers with Mild Chronic Hypertension Maternal Follow-Up
Obstetrics & Gynecology
Adult
VHIRB-The Chronic Hypertension and Pregnancy (CHAP) Project randomized pregnant women with mild chronic hypertension (CHTN) to usual care (i.e. antihypertensive therapy only if the patient experienced severe hypertension defined as systolic blood pressure (SBP) =160 mmHg or diastolic blood pressure (DBP) =105 mmHg) or to intervention (i.e. antihypertensive therapy to goal BP < 140/90 mmHg).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
CIRB, Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Symptom Management
Cancer Symptom Management
Adult, Child
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the Wisebag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
Lorem ipsum dolor sit amet
Knecht, Justin E
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla bibendum et eros in ultricies. Duis pellentesque urna orci, vel ultrices turpis sagittis id. Vivamus quis mauris mi. Vivamus sagittis a magna ut convallis. Etiam scelerisque a enim sed pretium. Etiam aliquet risus ligula, vel bibendum dolor pretium eget. Maecenas fermentum et quam at dictum. Integer rhoncus ex luctus, ultricies elit eu, finibus velit. Mauris tempor sapien nec odio molestie tincidunt.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ORCA: TEST - Milestones
Testing Financial Functions
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ORCA: Test - Milestone Incorrectly Achieved
Testing use case: Event Incorrectly Achieved
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ORCA: TEST - Financial Testing
Testing functionality
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449